Literature DB >> 27628693

Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

S K Powell1, N Khan1, C L Parker1, R J Samulski1,2, G Matsushima3, S J Gray1,4, T J McCown1,5.   

Abstract

No adeno-associated virus (AAV) capsid has been described in the literature to exhibit a primary oligodendrocyte tropism when a constitutive promoter drives gene expression, which is a significant barrier for efficient in vivo oligodendrocyte gene transfer. The vast majority of AAV vectors, such as AAV1, 2, 5, 6, 8 or 9, exhibit a dominant neuronal tropism in the central nervous system. However, a novel AAV capsid (Olig001) generated using capsid shuffling and directed evolution was recovered after rat intravenous delivery and subsequent capsid clone rescue, which exhibited a >95% tropism for striatal oligodendrocytes after rat intracranial infusion where a constitutive promoter drove gene expression. Olig001 contains a chimeric mixture of AAV1, 2, 6, 8 and 9, but unlike these parental serotypes after intravenous administration Olig001 has very low affinity for peripheral organs, especially the liver. Furthermore, in mixed glial cell cultures, Olig001 exhibits a 9-fold greater binding when compared with AAV8. This novel oligodendrocyte-preferring AAV vector exhibits characteristics that are a marked departure from previously described AAV serotypes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27628693      PMCID: PMC5541369          DOI: 10.1038/gt.2016.62

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  34 in total

1.  Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.

Authors:  Dawn E Bowles; Scott W J McPhee; Chengwen Li; Steven J Gray; Jade J Samulski; Angelique S Camp; Juan Li; Bing Wang; Paul E Monahan; Joseph E Rabinowitz; Joshua C Grieger; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Xiao Xiao; R Jude Samulski
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

2.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

3.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.

Authors:  Michael S Rafii; Tiffany L Baumann; Roy A E Bakay; Jeffrey M Ostrove; Joao Siffert; Adam S Fleisher; Christopher D Herzog; David Barba; Mary Pay; David P Salmon; Yaping Chu; Jeffrey H Kordower; Kathie Bishop; David Keator; Steven Potkin; Raymond T Bartus
Journal:  Alzheimers Dement       Date:  2014-01-07       Impact factor: 21.566

5.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

6.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.

Authors:  Steven J Gray; Stacey B Foti; Joel W Schwartz; Lavanya Bachaboina; Bonnie Taylor-Blake; Jennifer Coleman; Michael D Ehlers; Mark J Zylka; Thomas J McCown; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2011-06-01       Impact factor: 5.695

7.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain.

Authors:  Cassia N Cearley; Luk H Vandenberghe; Michael K Parente; Erin R Carnish; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

8.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle.

Authors:  Aravind Asokan; Julia C Conway; Jana L Phillips; Chengwen Li; Julia Hegge; Rebecca Sinnott; Swati Yadav; Nina DiPrimio; Hyun-Joo Nam; Mavis Agbandje-McKenna; Scott McPhee; Jon Wolff; R Jude Samulski
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

9.  Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain.

Authors:  Ethan G Hughes; Shin H Kang; Masahiro Fukaya; Dwight E Bergles
Journal:  Nat Neurosci       Date:  2013-04-28       Impact factor: 24.884

10.  Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.

Authors:  W San Sebastian; L Samaranch; G Heller; A P Kells; J Bringas; P Pivirotto; J Forsayeth; K S Bankiewicz
Journal:  Gene Ther       Date:  2013-09-26       Impact factor: 5.250

View more
  24 in total

1.  Viral Vector Reprogramming of Adult Resident Striatal Oligodendrocytes into Functional Neurons.

Authors:  Marc S Weinberg; Hugh E Criswell; Sara K Powell; Aadra P Bhatt; Thomas J McCown
Journal:  Mol Ther       Date:  2017-02-13       Impact factor: 11.454

2.  Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS.

Authors:  Jerusha Naidoo; Lisa M Stanek; Kousaku Ohno; Savanah Trewman; Lluis Samaranch; Piotr Hadaczek; Catherine O'Riordan; Jennifer Sullivan; Waldy San Sebastian; John R Bringas; Christopher Snieckus; Amin Mahmoodi; Amir Mahmoodi; John Forsayeth; Krystof S Bankiewicz; Lamya S Shihabuddin
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 3.  Strategies for delivering therapeutics across the blood-brain barrier.

Authors:  Georg C Terstappen; Axel H Meyer; Robert D Bell; Wandong Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-03-01       Impact factor: 84.694

Review 4.  Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.

Authors:  Maria Yanqing Chen; Susan S Butler; Weitong Chen; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-11-08

5.  Of Molecules and Mechanisms.

Authors:  Deanna L Benson
Journal:  J Neurosci       Date:  2019-10-19       Impact factor: 6.167

6.  Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA.

Authors:  Heng Li; Hironori Okada; Sadafumi Suzuki; Kazuhisa Sakai; Hitomi Izumi; Yukiko Matsushima; Noritaka Ichinohe; Yu-Ichi Goto; Takashi Okada; Ken Inoue
Journal:  JCI Insight       Date:  2019-05-16

7.  Astrocyte-specific deletion of the transcription factor Yin Yang 1 in murine substantia nigra mitigates manganese-induced dopaminergic neurotoxicity.

Authors:  Edward Pajarillo; James Johnson; Asha Rizor; Ivan Nyarko-Danquah; Getinet Adinew; Julia Bornhorst; Michael Stiboller; Tania Schwerdtle; Deok-Soo Son; Michael Aschner; Eunsook Lee
Journal:  J Biol Chem       Date:  2020-09-06       Impact factor: 5.157

8.  Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.

Authors:  Stefanie Grosse; Magalie Penaud-Budloo; Anne-Kathrin Herrmann; Kathleen Börner; Julia Fakhiri; Vibor Laketa; Chiara Krämer; Ellen Wiedtke; Manuel Gunkel; Lucie Ménard; Eduard Ayuso; Dirk Grimm
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

9.  AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo.

Authors:  Sara K Powell; R Jude Samulski; Thomas J McCown
Journal:  Mol Ther       Date:  2020-03-17       Impact factor: 11.454

Review 10.  Two-photon probes for in vivo multicolor microscopy of the structure and signals of brain cells.

Authors:  Clément Ricard; Erica D Arroyo; Cynthia X He; Carlos Portera-Cailliau; Gabriel Lepousez; Marco Canepari; Daniel Fiole
Journal:  Brain Struct Funct       Date:  2018-05-11       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.